SO30: Compliance and impact of colonoscopy in familial adenomatous polyposis and MYH-associated polyposis

Carmen Guillén-Ponce1, María-Teresa Salazar-López4, Beatriz Peñas2, Jesús Solera3, Pilar Martínez3, Vanessa Pachón-Olmos1, Reyes Ferreiro1, Julie Earl1, María-Isabel Humanes1.

1 – Oncology Department, Ramon y Cajal University Hospital, IRYCIS, MADRID, Spain. Red Temática de Investigación Cooperativa en Cancer, Instituto Carlos III, Spanish Ministry of Science and Innovation. 2 – Digestive Department, Ramon y Cajal University Hospital, MADRID, Spain. 3 – Molecular Genetic Laboratory, La Paz University Hospital, MADRID, Spain. 4 – Oncology Department, Ramon y Cajal University Hospital, IRYCIS, MADRID, Spain.

Aim

The aim of this study was to determine the compliance and impact of colonoscopy follow-up in individuals with familial adenomatous polyposis (FAP) and MYH-associated polyposis (MAP), in terms of the detection of cancer.

Method

Between 02/12/2011 and 12/31/2015, 27 individuals underwent regular follow-up. All patients met clinical criteria of FAP or MAP, and underwent a genetic study of APC or MUTYH genes. 13 had a pathogenic mutation; 7 had variants of unknown significance [VUS]; 7 had a non-informative result. Compliance and results of the colonoscopies were evaluated annually.

Results

Of the 27 individuals, 9 (33.3%) did not perform the recommended screening. The reasons were: 3 (11.1% of 27) physician didn’t prescribe the tests; 3 (11.1%) due to the patient; 3 (11.1%) other reasons. Out of 9 patients that don’t complete the colonoscopies, there was a lost of contact in 6 of those patients (22.2% of 27). During the follow-up period, one patient was diagnosed of rectal cancer.

Conclusion

Almost one third of the patients with PAF and MAP do not meet the recommended colonoscopies. The most important limitation for compliance is either physicians or patients. 22% of individuals leave the screening. Colonoscopy can detect colorectal cancer during the follow-up.

Top